Revolution Medicines

Today at @AACR, we announced updated clinical data from two Phase 1/2 trials evaluating our RAS(ON) multi-selective inhibitor in patients with previously untreated metastatic pancreatic cancer. Read more: ir.revmed.com/news-releases/… #AACR26 #PancreaticCancer

We presented preclinical data highlighting an innovative new class of mutant-targeted catalytic RAS(ON) inhibitors at the @AACR Annual Meeting today. Read more: ir.revmed.com/news-releases/… #AACR26

We will present detailed results from the Phase 3 RASolute 302 clinical trial during a Plenary Session at the @ASCO Annual Meeting. Learn more: ir.revmed.com/news-releases/… #ASCO26

Today we announced updated Phase 1 data for our RAS(ON) G12D-selective inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer at the @AACR Annual Meeting. More: ir.revmed.com/news-releases/… #AACR26 #LungCancer

Thank you @drughunter_com for recognizing our investigational RAS(ON) inhibitor as 2025 Molecule of the Year. We're honored and remain committed to advancing innovation and new treatment approaches for patients with RAS-driven cancers. drughunter.com/articles/darax…

Unprecedented overall survival benefit from Phase 3 RASolute 302 in previously treated metastatic pancreatic cancer. Read the press release: ir.revmed.com/news-releases/… #Oncology #PancreaticCancer

Study participants have started treatment in RASolute 303, a global Phase 3 trial evaluating our investigational therapy as first line treatment for patients with metastatic pancreatic cancer. Learn more: ir.revmed.com/news-releases/…

A new @PennCancer study shows how a cancer interception strategy can target pancreatic cancer before it forms: spr.ly/6012B6Kg3Q @ScienceMagazine @BenStanger01 @BasserBRCA

We will have 9 oral & poster presentations at @AACR in San Diego (April 17-22). Presentations reflect breadth of our RAS(ON) pipeline, with data spanning multiple tumor types, including ongoing efforts to address resistance in RAS driven cancers. More: ir.revmed.com/news-releases/…

Revolution Medicines presents at the @AACR Special Conference on RAS (March 7, Los Angeles), including a keynote from Mallika Singh, SVP Translational Research: "Targeting the oncogenic state of RAS: Lessons from tri-complex inhibitors" #AACRras26

We're proud to announce @My_Green_Lab has recertified all Revolution Medicines labs, with 100% achieving Green Level, the highest certification level. This accomplishment reflects our commitment to sustainable laboratory practices across the organization. #SustainableScience

We're joining X on #WorldCancerDay 🧬 Millions of patients and families facing cancer deserve better options. For those with RASmutant cancers, advancing innovative therapies offers hope. Today, we honor patients, caregivers, and researchers who are leading the way.